Phase II Trial With Safety Run-in of the Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine for Mesothelin Expressing Lung Adenocarcinoma

Trial Profile

Phase II Trial With Safety Run-in of the Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine for Mesothelin Expressing Lung Adenocarcinoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Oct 2017

At a glance

  • Drugs Anetumab ravtansine (Primary)
  • Indications Adenocarcinoma; Lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 21 Jun 2017 Planned End Date changed from 27 Apr 2020 to 26 Apr 2021.
    • 21 Jun 2017 Planned primary completion date changed from 29 Apr 2019 to 27 Apr 2020.
    • 31 May 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top